SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing increased social media activity and speculative interest as traders track its recent volatility and volume-driven price movements. Community members are actively debating the token's potential for a momentum-based squeeze while remaining divided between those accumulating for a rebound and those skeptical of its long-term viability.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is experiencing high volatility and intense community speculation following a major earnings beat and upward revenue guidance, which many traders are interpreting as an inflection point for the company's data center and optical infrastructure business. While long-term bulls point to design wins and AI demand as justification for the price surge, skeptics are actively debating whether the move is an overextended short squeeze that will inevitably face a sharp retracement.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is generating community buzz as investors highlight its low circulating supply and potential for growth within the decentralized finance sector, with many discussing its role in future leverage-focused products. While some participants express frustration over recent price volatility and lack of volume, proponents are actively calling for accumulation in anticipation of a potential breakout.

The Sandbox is a community-driven platform where creators can monetize voxel ASSETS and gaming experiences on the blockchain.  SAND is the utility token used throughout The Sandbox ecosystem as the basis of transactions and interactions. It is an ERC-20 utility token built on the Ethereum blockchain. There is a finite supply of 3,000,000,000 SAND.

The Sandbox

The Sandbox (SAND) is rallying as part of a broader resurgence in gaming and metaverse tokens, fueled by massive trading volume and community optimism regarding potential market-wide altseason cycles. Investors are actively debating the asset's long-term utility and historical cyclicality, with many using recent price dips to accumulate positions in anticipation of a significant breakout.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is trending as investors digest a strong earnings report featuring record product revenue, positive EBITDA, and improved margins, while the community focuses on the strategic potential of its recent StereoLabs acquisition for Physical AI applications. Enthusiasts are actively debating the firm's long-term growth as a unified perception platform, bolstered by institutional interest and high analyst price targets.

Chip

Chip is experiencing intense volatility and community debate following its simultaneous listing on major trading platforms like Robinhood and Coinbase, which has driven massive speculative volume. Investors are divided between those betting on its long-term potential as an AI infrastructure utility token and skeptics who are labeling the rapid price swings as a classic pump-and-dump scheme.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II ($CEPT) is drawing significant community interest as it nears its anticipated merger with Securitize, a leader in real-world asset tokenization backed by major institutions like BlackRock. Investors are actively monitoring SEC filings and potential ticker changes while debating the stock's long-term potential as a pure-play infrastructure investment in the tokenization sector.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is gaining significant attention following the announcement of its new vKAT tokenomics and ve-style accrual system, fueling community speculation about its potential as a top market cap contender. Traders are actively debating the token's recent price volatility and consolidation patterns, with many focusing on its integration with major decentralized finance liquidity protocols.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume amid heavy speculation regarding a potential strategic partnership with Amazon and its role within the broader AI semiconductor ecosystem. The community is actively debating the stock's parabolic move, with many bulls focusing on a short squeeze as the primary driver while cautioning that significant execution risks remain.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is experiencing heightened volatility and intense social media discussion as the community balances anticipation for the GTA VI launch with concerns over potential game delays and the impact of emerging AI development tools. Investors are actively tracking management commentary on release timelines, with sentiment split between those viewing recent price dips as a long-term buying opportunity and those fearful of further setbacks to the product pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences.</li><li>The firm believes Harmony’s Wakix franchise should be viewed as protected and fully intact through 2030.</li><li>Mizuho also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.</li></ul>Shares of Harmony Biosciences Holdings Inc. (HRMY) soared more than 18% in Tuesday’s midday trade after analysts at Mizuho announced that they have learned of a new patent lawsuit filed by the company.According to TheFly, Mizuho analysts stated that Harmony Biosciences has sued AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.<a href="https://stocktwits.com/symbol/HRMY">Harmony Biosciences shares</a> were up over 14% in Tuesday’s midday trade. Retail sentiment on Stocktwits about the company trended in ‘bullish’ territory, with message volume at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Is The Lawsuit About?</h2>Mizuho stated in its note that AET Pharma is the sole remaining generic challenger that has yet to settle with Harmony Biosciences. The lawsuit covers pitolisant, which was initially developed by Bioprojet and subsequently licensed exclusively by Harmony for the development, manufacture, and commercialization of pitolisant in the U.S.The firm now believes the Harmony Wakix franchise should be considered protected and fully intact through 2030. It also noted that Harmony's lawsuit is a "significant development" and a "major positive" for the company.Mizuho contended that this lawsuit should also remove a major overhang on HRMY stock stemming from concerns that a generic version of pitolisant could be launched before 2030.The firm reiterated its ‘Outperform’ rating on Harmony, with a $50 price target, implying an upside of about 50% from current levels.Koyfin data shows that the average 12-month price target for Harmony is $42, implying an upside of about 27% from current levels. Of the 11 analysts covering the stock, six have either a ‘Strong Buy’ or a ‘Buy’ recommendation, four have a ‘Hold’ rating, and one has a ‘Strong Sell’ recommendation.<h2 class="st-heading-2">What Is Pitolisant Used For?</h2>Pitolisant, originally developed to treat excessive daytime sleepiness and cataplexy in narcolepsy patients, is also being evaluated by Harmony Biosciences for use in individuals with Prader-Willi syndrome.The company also has two pitolisant tablet formulations, namely Pitolisant GR and Pitolisant HD.Harmony is developing Pitolisant GR to enable treatment initiation within the therapeutic dose range. Pitolisant HD is a reformulated version designed to improve how the drug works in the body and to target additional symptoms, such as fatigue, in patients with narcolepsy.Harmony announced in February this year that the U.S. Food and Drug Administration (FDA) approved Wakix (pitolisant) for the treatment of cataplexy in pediatric narcolepsy.“With this approval, clinicians now have the option to prescribe WAKIX to treat excessive daytime sleepiness, cataplexy, or both, in patients 6 years and older with narcolepsy,” said Harmony Biosciences’ Chief Medical and Scientific Officer, Kumar Budur.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> is down 10% year-to-date, but up 18% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 43% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 51%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/velo-stock-soars-best-gains-4-months-what-is-fueling-rally/cZBI8d9RI6e">VELO Stock Soars 38%, Races Toward Best Single-Day Move In 4 Months — What Is Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say?

Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.

Equity

Best-Performing Leveraged ETFs of Last Week

Leveraged ETFs like IONL and HIMZ surged last week on easing Iran war fears, strong earnings and quantum buzz, even as Strait of Hormuz risks persist.

Top-Performing ETFs of Last Week 

ETFs rallied last week on easing Iran war fears, strong earnings and crypto buzz, even as Strait of Hormuz risks linger.

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

<ul class="summary-bullets"><li>The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.</li><li>Yartemlea is the first and only FDA-approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy.</li><li>The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.</li></ul> Shares of Omeros Corp. (OMER) are on track to close their best week since late December, if gains hold, after the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.Yartemlea is the first and only approved medicine for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The condition can hit people after a stem cell or bone marrow transplant and is a rare, severe, and potentially fatal complication where microscopic blood clots form in small vessels, damaging organs, particularly the kidneys and brain.The company said on Thursday that the J-code will become effective on July 1.<h2 class="st-heading-2">What Is The J-Code?</h2>A J-code is an official “billing sticker” that doctors and hospitals use when they give a patient non-orally administered medications, such as injections, infusions, and chemotherapy. A permanent J-code is designed to simplify billing and speed up reimbursement for a treatment when used by patients covered by Medicare, Medicaid and most commercial insurance plans.Omeros said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics.“For patients with TA-TMA, access to effective treatment without unnecessary delay is critical,” said CEO Gregory A. Demopulos. “The assignment of a permanent, product-specific J-code for YARTEMLEA establishes a clear and consistent reimbursement pathway across payors, reducing administrative burden, supporting faster access for patients, and delivering more predictable reimbursement for providers.”The U.S. Food and Drug Administration approved Yartemlea in December for the treatment of TA-TMA in adults and children aged two years and older. The company is now eyeing an approval for the treatment by the European Medicines Agency by mid-2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user highlighted the company’s partnership with Danish drugmaker Novo Nordisk (NVO).<stembedurl>https://www.stocktwits.com/resq1/message/650620063</stembedurl>Omeros and Novo entered into a definitive asset purchase and license agreement in October for the candidate drug zaltenibart in clinical development for rare blood and kidney disorders. Under the deal, Omeros is eligible to receive up to $2.1 billion, including milestone payments.Yet another Stocktwits user applauded the J-code as “actually huge” and voiced optimism for it driving commercial acceleration of Yartemlea.<stembedurl>https://www.stocktwits.com/mjk49/message/650580855</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained about 97% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf">PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment

Omeros said that the U.S. Centers for Medicare and Medicaid Services assigned a permanent J-code for its recently-approved treatment Yartemlea.

<ul class="summary-bullets"><li>UBS stated in its note that the competitive intensity in the battery energy storage systems space is increasing.</li><li>The firm cited the Trump administration’s tax policy, which incentivizes auto manufacturers to shift from battery production for electric vehicles to utility-scale BESS.</li><li>UBS expects an oversupply of BESS starting in 2027, which will push costs down and increase pressure on Fluence Energy’s margins.</li></ul>Shares of Fluence Energy Inc. (FLNC) could be in for further decline after falling more than 24% year to date, with UBS analysts flagging concerns about battery oversupply.According to TheFly, UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22. The firm’s new price target implies a 43% downside from Fluence Energy’s Thursday closing price.<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy shares</a> were down more than 9% in Friday’s pre-market trade.<h2 class="st-heading-2">UBS Highlights Increasing Competitive Intensity</h2>UBS stated in its note that competitive intensity in the battery energy storage systems (BESS) space is increasing, citing the Trump administration’s tax policy that incentivizes auto manufacturers to shift production from batteries for electric vehicles to utility-scale BESS.The firm expects an oversupply of BESS starting in 2027, which will push costs down and thereby increase pressure on Fluence’s margins. UBS added that the market currently “significantly underappreciates” the manufacturing capacity additions of BESS due to U.S. tax policies for the sector.Analysts at Goldman Sachs also trimmed their price target for Fluence Energy to $20 from $28 while keeping a ‘Buy’ rating on the stock. The firm stated that it expects the first quarter (Q1) to be a “noisy” one for the company.Barclays analysts noted that while Fluence Energy has resolved the tax credit risk after its supplier retained compliance with the Foreign Entity of Concern rules, the Middle East shipping disruptions due to the Iran war could result in Fluence missing second-quarter (Q2) sales estimates. Barclays lowered its price target for Fluence Energy to $16 from $20, while maintaining an ‘Equal Weight’ rating.Fluence Energy reaffirmed earlier this month the continued availability of its U.S.-manufactured products that qualify for tax incentives under the One Big Beautiful Bill Act.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/FLNC">Fluence Energy</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/FLNC">FLNC stock</a> is down 24% year-to-date, but up 312% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 46% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/envb-stock-on-track-worst-decline-10-weeks-enveric-private-placement/cZJUl4KRIx0">ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Fluence Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FLNC Stock Has Dropped 24% This Year — And More Pain May Be Coming Due To Trump Administration’s Tax Policies

UBS downgraded Fluence Energy to ‘Sell’ from ‘Neutral’ and lowered its price target by 64% to $8 from $22, which implies a 43% downside from the closing price on Thursday.

<ul class="summary-bullets"><li>Earlier this week, Credo announced an acquisition of DustPhotonics, a developer of Silicon Photonics Photonic Integrated Circuit technology for optical transceivers.&nbsp;</li><li>Goldman Sachs analyst James Schneider noted Credo's acquisition of DustPhotonics, saying the deal would accelerate its expansion into optical networking.&nbsp;</li><li>According to data from Koyfin, analysts covering CRDO stock have a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.</li></ul>Shares of Credo Technology Group Holding (CRDO) have rallied more than 46% in the past 5 days, gaining attention from investors and Wall Street analysts alike.The company has been riding the wave of optimism over its <a href="https://stocktwits.com/news-articles/markets/equity/crdo-stock-soars-post-market-on-dustphotonics-acquisition/cZJ8QyZRIuy">acquisition of DustPhotonics</a>, a developer of Silicon Photonics Photonic Integrated Circuit (SiPho PIC) technology for optical transceivers, announced earlier this week.Following the news, Jefferies raised its price target on Credo to $225 from $175, while maintaining a ‘Buy’ rating on the stock, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/analyst-ratings/jefferies-raises-credo-technology-stock-price-target-on-optics-growth-93CH-4619456">according</a> to Investing.com. The updated target represents an upside potential of about 41.6% from the last close.Earlier in the day, Goldman Sachs also raised the price target on Credo to $170 from $150 and kept a ‘Buy’ rating on its shares, as per TheFly.<h2 class="st-heading-2">Street Consensus</h2>Jefferies said that it increased its estimates after Credo’s acquisition of DustPhotonics and the company’s guidance for more than $500 million in total Optics revenue for fiscal 2027. The analyst expects Credo’s Optics business in FY27 to generate approximately $125 million in Optical DSP revenue, more than $300 million in ZF Optics, and approximately $75 million in standalone PIC revenue.Goldman Sachs analyst James Schneider also noted Credo's acquisition of DustPhotonics, saying that the deal would accelerate its expansion into optical networking and strengthen confidence in its diversification beyond copper-based active electrical cables, with improved visibility toward its $500 million optical revenue target by FY27, the analyst said.Meanwhile, Bank of America raised its price target on the company to $210 from $160 and kept a ‘Buy’ rating on the shares after the acquisition. Rosenblatt analyst Mike Genovese also raised the firm's price target on Credo to $175 from $125 and kept a ‘Neutral’ rating on the shares.According to data from Koyfin, 16 out of 17 analysts covering CRDO stock have a ‘Buy’ or higher rating on it, with a 12-month average price target of $204.59, indicating an upside potential of about 28.7%.<h2 class="st-heading-2">Stronger AI Connectivity</h2>Credo’s acquisition of DustPhotonics is aimed at strengthening its optical interconnect roadmap and expanding its footprint in the global optical market. DustPhotonics’ silicon photonics technology will enhance performance, lower costs, and improve reliability for AI data centers, while boosting Credo’s ZeroFlap platform and reducing supply dependencies, the company said.Credo also said that it sees this as a key inflection point, expecting its optical business to surpass $500 million in revenue by FY27, supported by growing hyperscale AI demand. CEO William Brennan called the deal a defining step toward leading AI connectivity.<h2 class="st-heading-2">Retail Reaction</h2>On Stocktwits, retail sentiment around CRDO stock was in the ‘extremely bullish’ territory amid ‘extremely high’ message volumes at the time of writing. Retail chatter around the stock has increased 79% in the past week.While <a href="https://stocktwits.com/symbol/CRDO">CRDO shares</a> closed down 5.6% on Thursday, they have rallied more than 321% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Credo Technology logo is displayed on a smartphone screen

CRDO Stock Has Surged 46% In The Past 5 Days — Does It Have Room For More Upside?

Jefferies raised its price target on Credo Technology to $225 from $175, indicating an upside potential of about 41.6% from last close. 

<ul class="summary-bullets"><li>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia’s Ising launch earlier this week reigniting momentum in the sector.</li><li>D-Wave Quantum CEO Alan Baratz told Yahoo Finance during an interview on Thursday that the company has already crossed the “ChatGPT moment” in quantum computing.</li><li>He credited this to a method known as quantum annealing, which uses quantum physics to find the problem's low-energy states.</li></ul>Shares of D-Wave Quantum Inc. (QBTS) gained nearly 8% in Thursday’s pre-market trade&nbsp;and are on track to cross the 100-day moving average for the first time since January this year.If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the company’s stock.<a href="https://stocktwits.com/symbol/NVDA">D-Wave shares</a> have surged more than 43% over the previous five trading sessions.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_16_at_7_01_31_AM_png_ddff2f3957.webp" alt="Screenshot 2026-04-16 at 7.01.31 AM.png" width="3326" height="1822"><figcaption>Source: TradingView</figcaption></figure><h2 class="st-heading-2">What Is Fueling The QBTS Rally?</h2>Quantum stocks have been on an upswing over the past few trading sessions, with AI bellwether Nvidia Corp.’s (NVDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jensen-huang-nvidia-ising-quantum-stocks-qbts-rgti-qubt-soar/cZJqfdwRIvd">Ising launch</a> earlier this week bringing back the momentum in the sector.On the sidelines of the Semafor World Economic Summit, D-Wave Quantum CEO Alan Baratz told Yahoo Finance&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/d-wave-ceo-says-quantum-computing-is-already-past-its-chatgpt-moment-214253705.html">during</a> an interview on Thursday that the company has crossed the “ChatGPT moment” for quantum computing already.Baratz credited this to a method known as quantum annealing, which uses quantum physics to find a problem's low-energy states. This technique is then used to arrive at the optimal or a near-optimal combination of elements. D-Wave’s computers are the most famous example of quantum annealers.D-Wave’s technology is currently being used in cellular networks and pharmaceutical supply chains.“For annealing, we've hit that point. For gate model systems. We're still a few years away from it,” Baratz added, while noting that it needs some more engineering.<h2 class="st-heading-2">Why Is This Important?</h2>D-Wave’s approach addresses the critical power-efficiency challenge currently facing the AI industry.Baratz stated in the interview that D-Wave’s quantum computers draw only 10 kilowatts to solve a problem and that the company’s technology can provide a solution within minutes, while a massive GPU cluster would require the “world’s power” and millions of years to achieve the same.On Tuesday, while announcing Ising, Nvidia CEO Jensen Huang stated that AI is essential to making quantum computing practical, as Nvidia’s new open AI model aims to help enterprises turn quantum processors into large-scale, reliable computers.“With Ising, AI becomes the control plane — the operating system of quantum machines — transforming fragile qubits to scalable and reliable quantum-GPU systems,” Huang said.This comes at a time when AI is expected to drive a surge in global electricity demand. According to an April 2025&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.iea.org/news/ai-is-set-to-drive-surging-electricity-demand-from-data-centres-while-offering-the-potential-to-transform-how-the-energy-sector-works">report</a> by the International Energy Agency, electricity demand from data centers worldwide is projected to more than double by 2030, to 945 terawatt-hours.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QBTS">QBTS</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user stated that quantum technology and nuclear are the future and hope of humanity.<stembedurl>https://stocktwits.com/QuantumKVY/message/650438448</stembedurl><a href="https://stocktwits.com/symbol/QBTS">QBTS stock</a> is down 20% year-to-date, but up 201% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 44% over the past 12 months, while the Vanguard Total Stock Market Index Fund ETF (VTI) is up 31%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-myse-stock-soaring-today/cZJvidNRID3">MYSE Stock Is Up More Than 200% Pre-Market Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, D-Wave Systems Inc. logo of a Canadian quantum computing company is seen on a smartphone screen. 

QBTS Stock On Track To Cross 100-DMA For First Time Since January After Gaining 43% In 5 Days — What Is Powering The Surge?

If D-Wave shares continue the pre-market momentum through the day, this would be the fifth consecutive day of gains for the stock.

Peak of Iran War Priced-In? Low-P/E High Momentum ETFs in Focus 

Markets may have priced in peak Iran war fears. With volatility easing, low P/E, high-momentum ETFs are emerging as smart bets for near-term gains.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF